Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.
The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Complete report is available at: http://www.radiantinsights.com/research/tregalizumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023
Tregalizumab, also known as BT-061, is a humanized mAb against the CD4 receptor. It works specifically on the immunoglobulin G (IgG)-like C2 type 1 domain of the CD4 receptor in Treg cells, inducing downstream phosphorylation events, leading to the activation of this important regulatory cell. The activation of Treg cells thus reduces the damaging effects of cytokines and T effector cells in active RA.
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tregalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tregalizumab for the top 6 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.
Radiant Insights is a platform...